Monoclonal
antibodies are developed by identical immune cells, which have a
therapeutic use. The crystallized fragments (Fc) protein and
glycoengineered antibodies are known as the next generation
antibodies. These monoclonal antibodies are immunoglobulin G (IgG)
type of molecules, which are attached to a glycan residue on
crystallisable fragment. Glycoengineering is the method by which
these antibodies are created. They have varied applications for the
treatment of diseases such as multiple sclerosis and cancers.
Ask
Sample Copy of Research:
https://www.coherentmarketinsights.com/insight/request-sample/2626
Global
Fc Protein and Glycoengineered Antibodies Market Drivers
Key
players in the market are focusing on research and development
activities and receiving approvals from regulatory bodies, which are
expected to boost the global Fc protein and glycoengineered
antibodies market growth over the forecast period.
For
instance, in 2016, Genentech Inc. received approval from the U.S.
Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab).
It is being used for the treatment of urothelial carcinoma. In March
2019, Tecentriq received its second approval from the U.S. FDA for
the treatment of small lung cancer. Furthermore, in November 2017, TG
Therapeutics, Inc. began its clinical trial of Ublituximab for the
treatment of multiple sclerosis. It is currently in third phase of
its clinical trial. Factors such as increasing product approvals and
robust pipeline are expected to drive the global fc protein and
glycoengineered antibodies market growth.
Global
Fc Protein and Glycoengineered Antibodies Market Regional Analysis
North
America region is expected to dominate in the global fc protein and
glycoengineered antibodies market due to factors such as product
launches, presence of leading manufacturers (such as F. Hoffmann
La-Roche Ltd.), and active research and development in the field.
Drugs such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo),
Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved
in the U.S. in 2013, 2018, 2016, and 2017 respectively.
Europe
is expected to witness significant growth in the global Fc protein
and glycoengineered antibodies market. Factors such as approval for
new drugs is expected to drive the Europe’s Fc protein and
glycoengineered antibodies market growth over the forecast period.
For instance, in 2018, Kyowa Hakko Kirin Co. Ltd. received an
approval from the European Commission to market the Poteligeo
antibody in the European market. It is the first biological product
that is being directed against chemokine receptor 4 (CCR4), which
will be used for the treatment of Sezary syndrome that has been
previously treated by systemic therapy. Such new drug approvals are
expected to propel Europe Fc protein and glycoengineered antibodies
market growth over the forecast period.
Global
Fc Protein and Glycoengineered Antibodies Market Key Players
Some
of the major players operating in the global Fc protein and
glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd.,
Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc,
Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex
Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.
Global
Fc Protein and Glycoengineered Antibodies Market Taxonomy
The
global Fc protein and glycoengineered antibodies market is segmented
on the basis of drug, application, and region.
By
Drug
-
Approved Drugs
-
Obinutuzumab (Gazyva)
-
Mogamulizumab (Poteligeo)
-
Atezolizumab (Tecentriq)
-
Durvalumab (Imfinzi)
-
Pipeline Drugs
-
Ublituximab
-
Others
By
Application
-
Oncology
-
Autoimmune Disease
-
Others
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/ongoing-insight/fc-protein-and-glycoengineered-antibodies-market-2626
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment